全文获取类型
收费全文 | 4193篇 |
免费 | 397篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 141篇 |
妇产科学 | 108篇 |
基础医学 | 428篇 |
口腔科学 | 80篇 |
临床医学 | 468篇 |
内科学 | 828篇 |
皮肤病学 | 55篇 |
神经病学 | 391篇 |
特种医学 | 364篇 |
外科学 | 493篇 |
综合类 | 122篇 |
一般理论 | 5篇 |
预防医学 | 425篇 |
眼科学 | 53篇 |
药学 | 358篇 |
中国医学 | 6篇 |
肿瘤学 | 262篇 |
出版年
2021年 | 38篇 |
2020年 | 32篇 |
2019年 | 48篇 |
2018年 | 72篇 |
2017年 | 54篇 |
2016年 | 64篇 |
2015年 | 68篇 |
2014年 | 92篇 |
2013年 | 121篇 |
2012年 | 208篇 |
2011年 | 192篇 |
2010年 | 116篇 |
2009年 | 135篇 |
2008年 | 186篇 |
2007年 | 165篇 |
2006年 | 168篇 |
2005年 | 127篇 |
2004年 | 123篇 |
2003年 | 131篇 |
2002年 | 107篇 |
2001年 | 107篇 |
2000年 | 115篇 |
1999年 | 118篇 |
1998年 | 79篇 |
1997年 | 94篇 |
1996年 | 99篇 |
1995年 | 94篇 |
1994年 | 83篇 |
1993年 | 84篇 |
1992年 | 86篇 |
1991年 | 83篇 |
1990年 | 96篇 |
1989年 | 83篇 |
1988年 | 86篇 |
1987年 | 91篇 |
1986年 | 84篇 |
1985年 | 57篇 |
1984年 | 48篇 |
1983年 | 51篇 |
1982年 | 55篇 |
1981年 | 46篇 |
1980年 | 38篇 |
1979年 | 28篇 |
1978年 | 35篇 |
1977年 | 48篇 |
1976年 | 38篇 |
1975年 | 34篇 |
1974年 | 31篇 |
1972年 | 32篇 |
1968年 | 27篇 |
排序方式: 共有4599条查询结果,搜索用时 15 毫秒
61.
Huang Z Dias R Jones T Liu S Styhler A Claveau D Otu F Ng K Laliberte F Zhang L Goetghebeur P Abraham WM Macdonald D Dubé D Gallant M Lacombe P Girard Y Young RN Turner MJ Nicholson DW Mancini JA 《Biochemical pharmacology》2007,73(12):1971-1981
Type 4 phosphodiesterases (PDE4) inhibitors are emerging therapeutics in the treatment of a number of chronic disorders including asthma, chronic obstructive pulmonary disease (COPD) and cognitive disorders. This study delineates the preclinical profile of L-454,560, which is a potent, competitive and preferential inhibitor of PDE4A, 4B, and 4D with IC50 values of 1.6, 0.5 and 1.2 nM, respectively. In contrast to the exclusive binding of cilomilast and the preferential binding of roflumilast to the PDE4 holoenzyme state (Mg2+-bound form), L-454,560 binds to both the apo-(Mg2+-free) and holoenzyme states of PDE4. The intrinsic enzyme potency for PDE4 inhibition by L-454,560 also results in an effective blockade of LPS-induced TNFalpha formation in whole blood (IC50 = 161 nM) and is comparable to the human whole blood potency of roflumilast. The cytokine profile of inhibition of L-454,560 is mainly a Th1 profile with significant inhibition of IFNgamma and no detectable inhibition of IL-13 formation up to 1 microM. L-454,560 was also found to be efficacious in two models of airway hyper-reactivity, the ovalbumin (OVA) sensitized and challenged guinea pig and the ascaris sensitized sheep model. Furthermore, L-454560 was also effective in improving performance in the delayed matching to position (DMTP) version of the Morris watermaze, at a dose removed from that associated with potential emesis. Therefore, L-454,560 is a novel PDE4 inhibitor with an overall in vivo efficacy profile at least comparable to roflumilast and clearly superior to cilomilast. 相似文献
62.
A 51-year-old woman presented with a large abdominopelvic mass suspicious on preoperative imaging for ovarian malignancy. At laparotomy, a large cystic mass was found originating from the uterus and adherent to the proximal ileum. Pathologic evaluation confirmed the diagnosis of cystic leiomyoma. 相似文献
63.
OBJECTIVE: To compare the incidence, mortality, and presentation of small cell carcinoma of the cervix with other histologies. METHODS: From 1977 to 2003, 290 women with small cell carcinoma of the cervix uteri were identified from the Surveillance, Epidemiology, and End Results database. Also, 27,527 patients with squamous cell carcinoma of the cervix and 5,231 patients with adenocarcinoma of the cervix were identified for comparison. The annual incidence was calculated and examined for trend. Patient and disease characteristics were compared among histologies. Univariable analyses were conducted using the log-rank test. Multivariable analysis was performed using Cox regression. RESULTS: The mean annual incidence for small cell carcinoma was 0.06 per 100,000 women, compared with 6.6 and 1.2 for squamous cell carcinoma and adenocarcinoma, respectively. There were significant differences at presentation between small cell carcinoma compared with squamous cell carcinoma and adenocarcinoma for race, treatment, International Federation of Gynecology and Obstetrics stage, and lymph node involvement (P<.05). A trend for improved survival was identified for adenocarcinoma (P=.036) and squamous cell carcinoma (P<.001) but not for small cell carcinoma (P=.672). Five-year survival for small cell carcinoma (35.7%) was worse compared with squamous cell carcinoma (60.5%, hazard ratio 0.55; 95% confidence interval (CI) 0.43-0.69) and adenocarcinoma (69.7%, hazard ratio 0.48; 95% CI 0.37-0.61). On multivariable analysis, age, stage, and race were prognostic for survival in women with small cell carcinoma (P<.05). CONCLUSION: Small cell carcinoma is a rare histology of cervical cancer associated with a worse prognosis and a predilection for nodal and distant metastasis. The decrease in survival was marked in early-stage and node-negative patients. Because of the high rates of nodal involvement even with early-stage disease, multimodality treatment with radiotherapy and chemotherapy should be considered. LEVEL OF EVIDENCE: II. 相似文献
64.
65.
Quantification in Patient Urine Samples of Felbamate and Three Metabolites: Acid Carbamate and Two Mercapturic Acids 总被引:1,自引:0,他引:1
Charles D. Thompson Mary T. Barthen Darrin W. Hopper Thomas A. Miller Mark Quigg Candice Hudspeth Georgia Montouris LaDonna Marsh James L. Perhach R. Duane Sofia Timothy L. Macdonald 《Epilepsia》1999,40(6):769-776
PURPOSE: Previously we proposed and provided evidence for the metabolic pathway of felbamate (FBM), which leads to the reactive metabolite, 3-carbamoyl-2-phenylpropion-aldehyde. This aldehyde carbamate was suggested to be the reactive intermediate in the oxidation of 2-phenyl-1,3-propanediol monocarbamate to the major human metabolite 3-carbamoyl-2-phenylpropionic acid. In addition, the aldehyde carbamate was found to undergo spontaneous elimination to 2-phenylpropenal, commonly known as atropaldehyde. Moreover, atropaldehyde was proposed to play a role in the development of toxicity during FBM therapy. Evidence for atropaldehyde formation in vivo was reported with the identification of modified N-acetyl-cysteine conjugates of atropaldehyde in both human and rat urine after FBM administration. Identification of the atropaldehyde-derived mercapturic acids in urine after FBM administration is consistent with the hypothesis that atropaldehyde is formed in vivo and that it reacts with thiol nucleophiles. Based on the hypothesis that the potential for toxicity will correlate to the amount of atropaldehyde formed, we sought to develop an analytic method that would quantify the amount of relevant metabolites excreted in patient urine. METHODS: We summarize the results of an LC/MS method used to quantify FBM, 3-carbamoyl-2-phenylpropionic acid and two atropaldehyde-derived mercapturic acids in the patient population. RESULTS: Analysis was performed on 31 patients undergoing FBM therapy. The absolute quantities of FBM and three metabolites were measured. CONCLUSIONS: This method demonstrated sufficient precision for the identification of patients exhibiting "abnormal" levels of atropaldehyde conjugates and may hold potential for patient monitoring. 相似文献
66.
Michael P. Farrell David J. Hughes Ian R. Berry David J. Gallagher Emily A. Glogowski Stewart J. Payne Michael J. Kennedy Róisín M. Clarke Susan A. White Cian B. Muldoon Fiona Macdonald Pauline Rehal Danielle Crompton Solvig Roring Sarah T. Duke Trudi McDevitt David E. Barton Shirley V. Hodgson Andrew J. Green Peter A. Daly 《Familial cancer》2012,11(3):509-518
Approximately 25 % of mismatch repair (MMR) variants are exonic nucleotide substitutions. Some result in the substitution of one amino acid for another in the protein sequence, so-called missense variants, while others are silent. The interpretation of the effect of missense and silent variants as deleterious or neutral is challenging. Pre-symptomatic testing for clinical use is not recommended for relatives of individuals with variants classified as ‘of uncertain significance’. These relatives, including non-carriers, are considered at high-risk as long as the contribution of the variant to disease causation cannot be determined. This results in continuing anxiety, and the application of potentially unnecessary screening and prophylactic interventions. We encountered a large Irish Lynch syndrome kindred that carries the c.544A>G (p.Arg182Gly) alteration in the MLH1 gene and we undertook to study the variant. The clinical significance of the variant remains unresolved in the literature. Data are presented on cancer incidence within five kindreds with the same germline missense variant in the MLH1 MMR gene. Extensive testing of relevant family members in one kindred, a review of the literature, review of online MMR mutation databases and use of in silico phenotype prediction tools were undertaken to study the significance of this variant. Clinical, histological, immunohistochemical and molecular evidence from these families and other independent clinical and scientific evidence indicates that the MLH1 p.Arg182Gly (c.544A>G) change causes Lynch syndrome and supports reclassification of the variant as pathogenic. 相似文献
67.
68.
69.
70.
Julia K. Archbold Whitney A. Macdonald Stephanie Gras Lauren K. Ely John J. Miles Melissa J. Bell Rebekah M. Brennan Travis Beddoe Matthew C.J. Wilce Craig S. Clements Anthony W. Purcell James McCluskey Scott R. Burrows Jamie Rossjohn 《The Journal of experimental medicine》2009,206(1):209-219
Human leukocyte antigen (HLA) gene polymorphism plays a critical role in protective immunity, disease susceptibility, autoimmunity, and drug hypersensitivity, yet the basis of how HLA polymorphism influences T cell receptor (TCR) recognition is unclear. We examined how a natural micropolymorphism in HLA-B44, an important and large HLA allelic family, affected antigen recognition. T cell–mediated immunity to an Epstein-Barr virus determinant (EENLLDFVRF) is enhanced when HLA-B*4405 was the presenting allotype compared with HLA-B*4402 or HLA-B*4403, each of which differ by just one amino acid. The micropolymorphism in these HLA-B44 allotypes altered the mode of binding and dynamics of the bound viral epitope. The structure of the TCR–HLA-B*4405EENLLDFVRF complex revealed that peptide flexibility was a critical parameter in enabling preferential engagement with HLA-B*4405 in comparison to HLA-B*4402/03. Accordingly, major histocompatibility complex (MHC) polymorphism can alter the dynamics of the peptide-MHC landscape, resulting in fine-tuning of T cell responses between closely related allotypes. 相似文献